" class="no-js "lang="en-US"> Ariel Katz - Medtech Alert
Friday, September 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ariel Katz

Ariel Katz

About Ariel Katz

Ariel started his first company in college, ResearchConnection, to help connect students with research opportunities. That company grew to over 40 universities and was eventually acquired by the Jefferson Accelerator Fund, Bill and Melinda Gates Foundation and the Ewing Kauffman Foundation.  In 2017, Ariel co-founded H1 to address issues in healthcare and has created the largest global healthcare network that connects healthcare professionals.

Related Story

Artificial Intelligence

 H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials | Pharmtech Focus

H1 and Lokavant Partner on Data and Analytics to Power Next Generation Clinical Trials

August 4 2022

H1, the connecting force for global HCP, clinical, scientific, and research information, and Lokavant, the […]

Clinical Trials

 H1 Secures an Extension on Its Series C to Further Its Mission of Creating a Healthier Future Through the Use of Connected and Accessible Healthcare Data | Pharmtech Focus

H1 Secures an Extension on Its Series C to Further Its Mission of Creating a Healthier Future Through the Use of Connected and Accessible Healthcare Data

June 10 2022

H1, the connecting force for global healthcare professional, clinical, science, and research information, announced today […]